Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27534910 | 0.87 | EPHX2 (0.54) | EPHX2IDO1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL25230746 | 0.84 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1HPGDMAPT | |
| SCHEMBL7688792 | 0.83 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1HPGDCYP3A4CYP2D6 | |
| SCHEMBL4523190 | 0.82 | SIRT2 (0.60) | ALDH1A1HPGDCYP3A4CYP2C9ALOX12 | |
| SCHEMBL7328828 | 0.82 | POLB (0.53) | EPHX2ALDH1A1 | |
| SCHEMBL393227 | 0.82 | EPHX2 (0.56) | EPHX2IDO1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL22922181 | 0.81 | CYP4F2 (0.59) | EPHX2IDO1ALDH1A1HTTMAPT | |
| SCHEMBL9251956 | 0.81 | SMN1; SMN2 (0.50) | IDO1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL16573272 | 0.80 | EPHX2 (0.55) | EPHX2SMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL14717782 | 0.80 | EPHX2 (0.56) | EPHX2IDO1ALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150561-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO S.A. (CH) | 2014-08-14 | — | — | US | disclosed |
| US-8802861-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | PF4, TEC, PDGFRB | EPHX2 4191/4885IDO1 2215/4885SMN1; SMN2 4287/4885 |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | EPHX2 4034/4885IDO1 1520/4885SMN1; SMN2 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.